Biosimilar Antibodies

Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody specifically designed to target eotaxin-1 (CCL11), a key chemokine involved in the recruitment of eosinophils to inflammatory sites. This antibody has significant potential for the study of allergic disorders, offering a precise tool for elucidating the role of eotaxin-1 in the pathogenesis of these conditions. Bertilimumab may facilitate the development of therapeutic strategies aimed at modulating immune responses in allergic diseases.

PF-03732010 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CDH3/P-cadherin. This antibody is composed of a human IgG1 type heavy chain and a human lambda (huλ) type light chain, with a predicted molecular weight of 142.7 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. PF-03732010 is designed for precise binding to CDH3, making it an essential tool for research focused on cellular adhesion processes and cancer biology.

GFB-024 is a recombinant humanized monoclonal antibody specifically designed to target the CB1 receptor, also known as CNR1. This antibody binds with high specificity and affinity, making it an essential tool for the study of CB1 receptor functions in various physiological and pathological processes. GFB-024 is ideal for applications in both basic research and therapeutic development related to the endocannabinoid system.

Nezutatug is a monoclonal antibody targeting the human epidermal growth factor receptor 3 (HER3), a protein implicated in the modulation of cell growth and differentiation. This antibody is specifically designed for use in cancer research, where it serves as a crucial tool for studying the role of HER3 in oncogenic processes and potential therapeutic interventions. Nezutatug is suitable for various experimental applications, including flow cytometry, Western blotting, and immunohistochemistry, making it a versatile reagent in the investigation of HER3's function and its involvement in cancer pathogenesis.

Derlotuximab is a chimeric antibody of the scFv-Fc (huIgG1) type, produced in Chinese Hamster Ovary (CHO) cells, and specifically targets Histone H1. This antibody has a predicted molecular weight of 145.1 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Birinkibart is a human monoclonal antibody of the IgG4κ subtype, specifically targeting the CSF2RB receptor. For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This specificity and configuration make Birinkibart suitable for detailed studies on CSF2RB-related pathways and potential therapeutic applications.

Urelumab is a fully human IgG4 monoclonal antibody that functions as a CD137 agonist without binding to its natural ligand. This antibody is designed to potentiate the antitumor activities of T-cells and natural killer (NK) cells. Additionally, Urelumab has been shown to potentially enhance the cytotoxic effects of Rituximab. It is primarily utilized in research focused on various non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and follicular lymphoma. This makes Urelumab a valuable tool in the study of immune-mediated cancer therapies.

Losatuxizumab is a monoclonal antibody targeting the Epidermal Growth Factor Receptor (EGFR). It exhibits high affinity for various forms of EGFR, with EC50 values of 0.96 nM for wild-type EGFR, 0.09 nM for the EGFRC271A,C283A mutant, 0.12 nM for EGFRvIII, and 0.66 nM for EGFR1-501. This antibody is specifically designed for the study of cancers expressing EGFR, making it an essential tool for research in oncology and molecular biology.

Osemitamab is a recombinant IgG1 monoclonal antibody specifically designed to target human claudin-18.2. This antibody is comprised of a human-Mus musculus monoclonal TST001 gamma 1-chain linked via disulfide bonds to a human-Mus musculus monoclonal TST001 kappa-chain, forming a dimeric structure. When used in conjunction with Capecitabine and Oxaliplatin, Osemitamab serves as a potent investigational tool for the study of gastric (G) and gastroesophageal junction (GEJ) cancers. This specificity and application make it a valuable asset for targeted cancer therapy research.

Anti-CEACAM7 Antibody (P3-7B) is a chimeric mouse monoclonal antibody of the IgG1, κ subclass, specifically designed to target human Carcinoembryonic Antigen-Related Cell Adhesion Molecule 7 (CEACAM7). This antibody has been developed for high specificity and affinity in recognizing the CEACAM7 antigen, making it ideal for detailed studies in cancer biology and immunology. For accurate experimental control, it is recommended to use Mouse IgG1 kappa, Isotype Control as the isotype control.

Tobevibart (VIR-3434) is a human IgG1 lambda monoclonal antibody specifically targeting the hepatitis B virus (HBV) surface antigen (HBsAg). Demonstrating potent in vitro neutralization capabilities, Tobevibart effectively inhibits HBsAg across all HBV genotypes and blocks viral entry for both HBV and the hepatitis delta virus (HDV). For experimental control purposes, the use of Human IgG1 lambda1 Isotype Control is recommended.

Lunlekitug is a human monoclonal antibody of the IgG1κ subtype that specifically targets interleukin-1 alpha (IL1A). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control. This antibody is designed for use in research studies examining the role and modulation of IL1A in various biological processes and disease states.

The Anti-CXCL8/IL-8 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the CXCL8/IL-8 chemokine. This antibody is structured with a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 145 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control serves as the appropriate isotype control for this antibody. This product is essential for research focused on inflammatory responses and chemotactic processes involving CXCL8/IL-8.

Tuparstobart (Incagn-02385) is an IgG1κ monoclonal antibody designed to specifically target LAG-3, an immune checkpoint receptor. LAG-3 is predominantly expressed on activated T cells, NK cells, B cells, and plasmacytoid dendritic cells. This antibody is engineered to bind to LAG-3, thereby modulating immune responses, which may be critical in the research of immune regulation and potential therapeutic applications in immune-related disorders.

Nelistotug (GSK 6097608; GSK6097608) is a human IgG1κ monoclonal antibody that specifically targets CD96. This antibody is designed for the precise identification and study of CD96 expression in various biological research applications. It is particularly useful in investigating the role of CD96 in immune response modulation and its potential implications in immunotherapy.

The Anti-CXCR4/CD184 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the CXCR4/CD184 receptor, a chemokine receptor implicated in various biological processes including cell migration, hematopoiesis, and tumor metastasis. This antibody is composed of a human IgG1 heavy chain and a human lambda light chain, and exhibits a molecular weight of approximately 145 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended.

Trabikibart (CSL311) is a βc (CSF2RB)-specific, fully human monoclonal antibody engineered to target a unique epitope on the cytokine-binding site of the human βc receptor. Exhibiting a picomolar binding affinity, this antibody effectively binds to the receptor, demonstrating robust specificity. Trabikibart acts as a potent inhibitor of the combined biological activities of IL-3, GM-CSF, and IL-5, particularly impacting the survival of eosinophils. This characteristic positions Trabikibart as a valuable tool for investigating the mechanisms underlying chronic inflammatory diseases and exploring potential therapeutic interventions.

Clenoliximab (IDEC-151) is a chimeric monoclonal antibody derived from macaque and human sources, classified within the immunoglobulin G4 subclass. It exhibits specificity for the CD4 molecule expressed on the surface of T lymphocytes. This antibody is primarily utilized in research focused on elucidating the pathophysiology and potential therapeutic interventions for rheumatoid arthritis.

MEDI-570 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting ICOS/CD278. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 145 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Setrusumab (BPS 804) is a fully human monoclonal antibody that specifically targets sclerostin, a protein involved in the negative regulation of bone formation. By inhibiting sclerostin, Setrusumab enhances bone formation and improves bone strength. This antibody is primarily utilized in research focused on Osteogenesis Imperfecta (OI) and various cancer models where bone density and strength are of interest. Setrusumab offers a valuable tool for researchers studying the pathophysiology and potential therapeutic interventions for disorders associated with compromised bone integrity.

Ecleralimab (CSJ-117; NVP-CSJ117) is a recombinant monoclonal antibody of the Fab-IgG1-λ2 subtype, specifically designed to target thymic stromal lymphopoietin (TSLP). This antibody is produced using a Chinese Hamster Ovary (CHO) cell expression system, ensuring high fidelity and stability in its structure and function. Ecleralimab is utilized primarily in research focused on understanding TSLP's role in immune response and potential therapeutic interventions.

Tafasitamab (XmAb5574) is an Fc-engineered, humanized monoclonal antibody specifically designed to target the CD19 antigen on human B-cell surfaces. This antibody's modifications enhance its binding affinity and efficacy in engaging immune effector functions, making it a critical tool in research focused on B-cell related diseases and therapeutics.

BI-765063 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting SIRPα (CD172a). This antibody is comprised of an IgG4PE heavy chain and a human kappa (huκ) light chain, with a predicted molecular weight of 144.36 kDa. For experimental control purposes, Human IgG4 kappa, Isotype Control is recommended. This antibody is suitable for a variety of research applications focusing on the modulation and study of SIRPα-mediated signaling pathways.

Torudokimab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-33 (IL-33). This antibody is constructed with a human IgG4SP heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 145.22 kDa. For experimental control purposes, Human IgG4 kappa, Isotype Control is recommended.

Relatlimab (BMS-986016) is a human monoclonal antibody targeting LAG-3, developed through the immunization of transgenic mice engineered to express human immunoglobulin miniloci, using recombinant LAG-3 protein. This antibody effectively inhibits the interaction between LAG-3 and MHC II with an IC50 of 0.67 nM, and between LAG-3 and FGL1 with an IC50 of 0.019 nM. It is primarily utilized in cancer research, providing a valuable tool for investigating the role of LAG-3 in tumor immune evasion and potential therapeutic interventions.

Nidanilimab (CAN04) is a fully humanized monoclonal antibody targeting IL1RAP, characterized by a high affinity with a dissociation constant (Kd) of 1.10 pM. This antibody effectively inhibits signaling pathways mediated by IL1α and IL1β, thereby enhancing immune system responses against tumor cells. Nidanilimab is primarily utilized in research focused on non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), offering significant potential for elucidating disease mechanisms and therapeutic interventions in these cancers.

Opugotamig is a chimeric antibody designed with a half-immunoglobulin G1 kappa (half-IG G1 -κ) framework and incorporates a single-chain variable fragment (scFv -κ-heavy) linked to the human IgG CH2 and CH3 domains. It specifically targets the folate receptor alpha (FOLR1), making it suitable for research into cellular processes mediated by this receptor, including studies on targeted drug delivery and cancer cell biology.

The Anti-oxLDL Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target oxidized low-density lipoprotein (oxLDL). This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This antibody is ideal for research applications focusing on the role of oxLDL in atherosclerosis and other related cardiovascular diseases.

Dostarlimab (TSR-042) is a humanized monoclonal antibody targeting PD-1 (Programmed Death-1). This antibody exhibits high affinity binding to PD-1, effectively blocking its interaction with the ligands PD-L1 and PD-L2. The inhibition constants (IC50) are determined to be 1.8 nM for PD-L1 and 1.5 nM for PD-L2, respectively. Dostarlimab serves as a potent inhibitor in the modulation of immune responses, making it a valuable tool in immunotherapy research.

Tilatamig is a human monoclonal antibody of the IgG1 subtype that specifically targets both EGFR and MET receptors. This dual specificity enables it to interfere with key pathways involved in cellular proliferation and survival, making it a valuable tool for research in cancer biology where these receptors are implicated.

CM-24 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CEACAM1/CD66a. This antibody has a predicted molecular weight of 145 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. CM-24 is designed for use in various immunological assays to study the function and role of CEACAM1/CD66a in biological processes.

Bevacizumab is a humanized IgG1 monoclonal antibody that exhibits high-affinity binding to all isoforms of vascular endothelial growth factor A (VEGF-A). This targeted binding inhibits the interaction of VEGF-A with its receptors, thereby modulating angiogenesis.

Imeroprubart is a human monoclonal antibody of the IgG1λ2 subtype that specifically targets FCGRT. For experimental control purposes, the recommended isotype control is Human IgG1 lambda2.

Risankizumab (BI 655066) is a humanized IgG monoclonal antibody that specifically targets the p19 subunit of interleukin-23 (IL-23), exhibiting a high binding affinity with a dissociation constant (Kd) of less than 10 pM. This antibody effectively inhibits the production of interleukin-17 (IL-17) induced by IL-23 in mouse splenocytes, demonstrating a half-maximal inhibitory concentration (IC50) of 2 pM. Risankizumab is primarily utilized in research focused on immunological and inflammatory disorders, including psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis, providing a valuable tool for understanding the pathophysiology and potential therapeutic interventions for these conditions.

Atinumab (NG-101) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets RTN4/NOGO, a protein implicated in the inhibition of neuronal growth and regeneration. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 146.62 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

NI-0801 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CXCL10/IP-10. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Rafivirumab (CR57) is a monoclonal antibody designed for the prophylaxis of rabies, demonstrating neutralizing potency against a wide range of rabies virus (RABV) variants. This antibody is particularly useful in research focused on the development of therapeutic antibody cocktails targeting diverse strains of RABV.

The Anti-PD-L1/B7-H1 Antibody (29E.2A3) is a chimeric mouse monoclonal antibody of the IgG2b, κ subclass, specifically designed to target human PD-L1, also known as B7-H1. This antibody has been developed for high specificity and affinity to PD-L1, an important immune checkpoint protein that plays a critical role in inhibiting the immune response, thereby enabling cancer cells to evade immune detection. For accurate experimental control, it is recommended to use the Mouse IgG2b kappa Isotype Control, which serves as a non-reactive baseline to assess the specific binding of the Anti-PD-L1/B7-H1 Antibody in various assays. This product is ideal for research applications focusing on cancer immunology and immune checkpoint regulation.

The Anti-GPRC5D Antibody is a humanized IgG1 monoclonal antibody specifically designed to target GPRC5D, a receptor expressed predominantly on multiple myeloma cells. This antibody serves as the targeting component of the antibody-drug conjugate (ADC) LM-305, utilized in targeted cancer therapy. For accurate experimental control, it is recommended to use Human IgG1 kappa as an isotype control. This product is essential for researchers focusing on oncology and therapeutic antibody development.

Uprevstobart is a human IgG1 κ monoclonal antibody targeting NT5E. For experimental control purposes, it is recommended to use Human IgG1 kappa Isotype Control.

The Anti-IL-12 p70 Antibody (20C2) is a chimeric rat IgG1, κ antibody specifically designed to target human IL-12 p70. For accurate experimental control, the recommended isotype control is Rat IgG1 kappa, Isotype Control. This antibody facilitates detailed study of IL-12 p70's role in immunological responses and its potential implications in inflammatory diseases.

The Anti-CSF1R/CD115 Antibody (2-4A5-4) is a chimeric monoclonal antibody derived from rat IgG1, κ, specifically designed to target human CSF1R/CD115. This antibody is ideal for investigating the biological functions and signaling pathways mediated by CSF1R/CD115. For accurate isotype control in experiments, it is recommended to use the Rat IgG1 kappa Isotype Control, ensuring specificity and consistency in antibody performance.

Bezlotoxumab is a human monoclonal antibody that targets Clostridium difficile toxin B. By binding to this toxin, Bezlotoxumab effectively prevents the associated damage to intestinal epithelial cells and the onset of colitis. This antibody serves as a crucial tool in the study of gastrointestinal diseases and therapeutic interventions for C. difficile infections.

Narlumosbart (JMT103) is a monoclonal antibody of the IgG4κ subtype designed to specifically target the receptor activator of nuclear factor-κB ligand (RANKL). This antibody is engineered to interact with RANKL, a critical mediator in the regulation of bone metabolism, immune interactions, and the development of lymphoid tissues. Narlumosbart is utilized primarily in research focused on bone diseases, immune system disorders, and cancer metastasis to bone.

Metelimumab (CAT-192) is a human IgG4 monoclonal antibody engineered to selectively neutralize transforming growth factor beta 1 (TGFβ1). This specificity makes it a valuable tool for researchers studying fibrosis, cancer progression, and other TGFβ1-related pathologies.

Ubletamig is a human IgG4 κ monoclonal antibody targeting MUC16. For experimental control purposes, it is recommended to use Human IgG4 kappa as an Isotype Control.

Coramitug is a human IgG1 κ monoclonal antibody targeting transthyretin (TTR). For experimental control purposes, it is recommended to use Human IgG1 kappa Isotype Control.

Ramucirumab is a recombinant human IgG1 monoclonal antibody specifically designed to target and antagonize vascular endothelial growth factor receptor 2 (VEGFR-2). By binding to the extracellular domain of VEGFR-2, Ramucirumab effectively inhibits the interaction with its natural ligands, VEGF-A, VEGF-C, and VEGF-D. This blockade disrupts the downstream signaling pathways that promote angiogenesis, making Ramucirumab a potent angiogenesis inhibitor. It is primarily utilized in the clinical management of various solid tumors, leveraging its mechanism to impair tumor vascularization and growth.